Department of Ophthalmology, University of California, San Francisco, San Francisco.
Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford.
Ophthalmic Plast Reconstr Surg. 2021;37(5):e160-e164. doi: 10.1097/IOP.0000000000001943.
A patient with thyroid-associated ophthalmopathy was treated with teprotumumab and developed symptoms concerning for inflammatory bowel disease after her sixth infusion. Colonoscopy was performed, and mucosal biopsies identified evidence of active colitis consistent with a diagnosis of ulcerative colitis. Despite treatment with budesonide and mesalamine, the patient continued to be symptomatic one and a half months after cessation of teprotumumab and required infliximab to achieve good control of her inflammatory bowel disease. This case represents the first report of new-onset inflammatory bowel disease arising during treatment with teprotumumab.
一位患有甲状腺相关眼病的患者接受了 teprotumumab 治疗，在第六次输注后出现了疑似炎症性肠病的症状。进行了结肠镜检查，黏膜活检显示存在符合溃疡性结肠炎诊断的活动性结肠炎证据。尽管使用布地奈德和美沙拉嗪进行了治疗，但在停止 teprotumumab 治疗一个半月后，患者仍有症状，需要使用英夫利昔单抗才能很好地控制炎症性肠病。本病例代表了首例在 teprotumumab 治疗期间出现的新发性炎症性肠病报告。
